Dimitrios P. Kontoyiannis


Acute, subacute and chronic aspergillosis remain major threats for human health, especially in immuno- 
suppressed hosts and patients with underlying structural lung disease. Despite significant strives, only 
three classes of molecules are currently used in clinical practice. The emerging azole resistance threats to 
devitalize the activity of the most commonly used drugs for that disease, the triazoles. In my lecture, I will 
summarize the unmet clinical needs of current antifungal therapy for aspergillosis, discuss the emerging 
pipeline and agents belonging to new molecular classes, the challenges inherent to antifungal drug discovery 
and development, and offer some perspectives for the future.


Full conference title: 

7th Advances Against Aspergillosis